This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk10: Good day and thank you for standing by. Welcome to the Ensign Group Inc. 4th Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I will now hand the conference over to Mr. Kitch.
spk02: Thank you, and welcome, everyone, and thank you for joining us today.
spk03: We filed our earnings press release yesterday, and it is available on the investor relations section of our website at nzinegroup.net. A replay of this call will also be available on our website until 5 p.m. Pacific on Friday, March 3, 2023. We want to remind any listeners that may be listening to a replay of this call that all statements are made as of today, February 3rd, 2023, and these statements have not been nor will be updated subsequent to today's call. Also, any forward-looking statements made today are based on management's current expectations, assumptions, and beliefs about our business and the environment in which we operate. These statements are subject to risks and uncertainties that could cause our actual results to materially differ from those expressed or implied on today's call. Listeners should not place undue reliance on forward-looking statements and are encouraged to review our SEC filings for a more complete discussion of factors that could impact our results. Except as required by federal securities laws, Enzyme and its affiliates do not undertake to publicly update or revise any forward-looking statements where changes arise as a result of new information, future events, changing circumstances, or for any other reason. In addition, the Enzyme Group, Inc. is a holding company with no direct operating assets, employees, or revenues. Certain of our wholly owned independent subsidiaries, collectively referred to as a service center, provide accounting, payroll, human resources, information technology, legal, risk management, and other services to the other operating subsidiaries through contractual relationships with such subsidiaries. In addition, our wholly owned captive insurance subsidiary, which we refer to as the insurance captive, provides certain claims-made coverage to our operating companies for general and professional liability, as well as for workers' compensation insurance liabilities. Enzyme also owns Standard Bear Healthcare REIT, Inc., which is a captive real estate investment trust that invests in healthcare properties and enters into lease agreements with certain independent subsidiaries of Enzyme, as well as third-party tenants that are unaffiliated with the Enzyme group. The words Ensign, Company, We, Our, and Us refer to the Ensign Group, Inc. and its consolidated subsidiaries. All of our operating subsidiaries, the Service Center, Standard Bearer, Healthcare REIT, and the Insurance Captive are all operated by separate, wholly owned, independent companies that have their own management employees and assets. References herein to the consolidated company and its assets and activities, as well as use of the terms We, Us, Our, and similar terms we may use today are not meant to apply, nor should it be construed as meaning that the Enzyme Group has direct operating assets, employees, or revenue, or that any of the subsidiaries are operated by the Enzyme Group. Also, we supplement our GAAP reporting with non-GAAP metrics. When viewed together with our GAAP results, we believe that these measures can provide a more complete understanding of our business, but they should not be relied upon to the exclusion of GAAP reports. A GAAP to non-GAAP reconciliation is available in yesterday's press release and is available in our Form 10-K. And with that, I'll turn the call over to Barry Port, our CEO. Barry?
spk08: Thank you, Chad, and thank you for joining us today. We were pleased to announce yesterday another record quarter. These results demonstrate yet again that our local leaders and their teams continue to be the examples of post-acute excellence as they wade through the evolving landscape in each of their markets. They have again achieved record results in spite of the continued disruption in the labor markets. Remarkably, we saw continued improvement in occupancies, skilled revenue, and managed care revenues. We were particularly pleased that we achieved sequential growth in overall occupancy for the eighth consecutive quarter, with same-store and transitioning operations increasing by 2.9% and 4.3%, respectively, over the prior year quarter. As of the end of the quarter, our same-store occupancy reached 77.8%, and we continue to get closer to our pre-COVID occupancy levels, which was at 80.1% in March of 2020. We are amazed by the commitment of our caregivers and their continued endurance and strength. We've also been very pleased with the progress we've made in improving our skilled mix. As those that have followed us know, growth in skilled mix only happens after our local teams demonstrate over and over that they can achieve successful outcomes for sicker patients that need more advanced care. During the quarter, our same-store operations grew their skilled mix revenue by 9.1% over the prior year quarter. Additionally, in the wake of the pandemic, there's been a lot of noise around potential shifts to home-based care or lack of support for inpatient post-acute services from hospitals and managed care providers. But when compared to pre-COVID levels, our skilled mix has remained elevated, showing just how important high-quality post-acute services are within the continuum of care. We've always been confident that our skilled mix would continue to be strong, but we are very pleased to see this continuous fundamental growth in skilled mix as it demonstrates the increasing and sustainable demand for skilled post-acute services without a significant impact from COVID. We continue to be impacted by the labor environment, but we are very encouraged by the improvement in several key internal performance areas that show that these issues are stabilizing. For example, we continue to see the rate of wage inflation slowing down, as we've experienced two quarters in a row of slower wage growth. In addition, while our use of agency labor is still higher than we'd like it to be, we are encouraged to see several markets becoming less and less reliant on agency labor. In addition, we also expect that as wage inflation moderates, that our need for agency labor will also continue to decrease. Lastly, we are also very pleased to see improvements in our employee turnover due to our leaders' relentless effort to create an employee-focused culture that aligns with our collective core values. Recently, the federal government extended the state of emergency to April 2023, which keeps in place many of the regulatory and other reforms of assistance helpful to patient care. Additionally, the government has indicated that the PHE will end in May of 2023. We also continue to benefit from FMAP-bolstered Medicaid funding in several states. some of which will end or phase out throughout the year. However, this federally supported funding will be replaced in large part with appropriate state-based funding, ensuring a relatively smooth transition. In addition to occupancy growth and continued skilled mix improvement, one major aspect of our company's resilience has been and continues to be our local leaders' ability to acquire struggling operations and transform them into facilities of choice for their communities. This ability combined with a strong balance sheet allows to increase the number of acquisitions we do in times of uncertainty when many operators are choosing or being forced to exit the industry. With the 17 acquisitions that we completed on February 1st, we have now added 37 affiliated operations since July 1st, 2022. We remain confident that our operating model will continue to allow each operator to form their own market-specific strategy and adjust to the needs of their local medical communities, including methods for attracting new healthcare professionals into our workforce and retaining and developing existing staff. These transitions will take time, particularly given the higher than normal reliance on agency staffing prior to the acquisition. But with each new operation, we are creating new opportunities for the next generation of leaders and look forward to working together to help each operation reach its enormous clinical and financial potential. I want to speak briefly about our ability to execute on the acquisition of a larger portfolio. In November, we announced that we had agreed to acquire 20 California buildings that have been operated by North American Healthcare, 17 of which we will operate. Just two days ago, we closed the transaction and we're very excited and encouraged with how things have gone so far. Over the last few months, we've had several investors ask us about our ability to execute on larger acquisitions while reminding us that the last larger deal we closed was the Legend transaction in Texas, which was a similar size. Those that were following us back in 2016 will remember that the legend transaction took several quarters to produce the results we expected. We were very open about the lessons we learned that made that transition a little more challenging than we anticipated. But as we look back, we worry we haven't done a good enough job at telling the massive success story that the legend operations have become. Those operations have been contributing a significant amount to our earnings for several years now and are currently achieving at least EBITDA coverage of 2.1 times. To give an even clearer picture, the EBITDA growth from acquisition until the end of 2022 has increased by over 160%. We certainly made some missteps early on in our approach to the legend acquisition, but even with those short-term setbacks, We would not be as strong as we are today in Texas without them and would definitely do that deal over and over again. I point to this example not to suggest that we expect the exact same results in this new portfolio. I do so only to underline how we look at acquisitions, including larger portfolios. We never acquire something for its short-term impact. We acquire a single building or 17 if and when we see significant opportunity create lasting long-term value to our portfolio. For the last several months, we have been preparing for these additions and have been implementing lessons learned in 2016 and 2017. All transitions take time, and we expect these will be no different, but we are thrilled and grateful to have the opportunity to work together with our new partners in this California portfolio, as well as the other geographies. and look forward to the contribution they will make to this organization over the next 20 years. As we evaluate our expanding portfolio, we see more organic growth potential within our existing portfolio than ever before. As we relentlessly follow and protect the cultural fundamentals that got us here, we are confident that we will continue to consistently produce world-class clinical and financial performance. We are very humbled by what we were able to accomplish in 2022 while dealing with so many unusual challenges. But we also know we can still do much better and are excited about the potential within our portfolio as we continue to apply our proven, locally driven healthcare model. We are issuing our annual 2023 earnings guidance of $4.60 to $4.74 per diluted share and annual revenue guidance of $3.55 billion to $3.62 billion. The midpoint of this 2023 earnings guidance represents an increase of 12.8% over our 2022 results and is 28.3% higher than our 2021 results. We are excited about the upcoming year and are confident that our partners will continue to manage and innovate through all of the lingering challenges on the labor front And when we consider the current health of our organization combined with our culture and proven local leadership strategy, we feel we are well positioned to have another outstanding year in 2023. Next, I'll ask Chad to discuss our recent growth. Chad?
spk03: Thank you, Barry. As we expected, we continue to add to our growing portfolio and are very excited about the 12 new operations we added during the quarter. These newly acquired operations include three skilled nursing operations in South Carolina, one skilled nursing operation in Arizona, six skilled nursing operations in Texas, and two skilled nursing operations in Colorado, totaling an additional 1,505 new operational beds. We always place the highest priority on growth opportunities within our existing footprint and are very excited about the addition to some of our most mature markets like Arizona and Colorado. Each of these operations were very carefully selected and will bolster our ability to fulfill the needs of our healthcare partners in geographies we didn't previously, or it simply enhances our service offerings in markets we have been in for years. We are also particularly excited about completing our first set of acquisitions in South Carolina since we entered that state several years ago. As we said before, entering new states is challenging and can often take time to gain the trust of the local healthcare community. Each of these operations in South Carolina is off to a great start. and we hope that we will be able to continue to build the Enzyme footprint in the Mid-Atlantic region. In addition, we also completed the previously announced acquisition of 20 skilled nursing operations in the state of California that have been operated by North American Healthcare. The real estate assets are all owned by Sabra Healthcare REIT and have been added to our long-term triple net master lease with them. As we said when we announced this transaction last November, We are honored that Sabra will be entrusting us with the operation of this portfolio and are very excited to expand our growing relationship with them. These California operations are a perfect fit with our existing footprint in some of our strongest and most mature markets, as well as giving us an opportunity to move into the Bay Area. As we evaluated the size and scope of the 20-building portfolio, there were three operations located in the Sacramento area that were geographic outliers for us. In addition, given the size and scope of the remaining 17 operations and the amount of resources that are necessary to transition that many operations at one time, we determined that the best course of action was to partner with another like-minded operator on those three operations. So as of February 1st, and with Sabra's consent, we entered into a sublease for the three Sacramento operations with Aspen Healthcare. In total, Enzyme Affiliates will operate 17 of the 20 buildings. adding 1,462 operational beds to Enzyme's portfolio, and Aspen will operate three of the 20 buildings, representing 245 operational beds. Just a side note, these subleased operations will not contribute to our overall performance. Aspen is a very reputable operator that currently operates 34 skilled nursing facilities in California. We have enormous respect for Aspen as an operator and believe that they are in a great position to build on the quality reputation these buildings already enjoy. They also have a strong balance sheet and have provided a company-level guarantee of their obligations under the sublease. As an aside, while this is not a situation where we own the real estate, as we've discussed for some time now, part of our strategy with our internal REIT is to expand our ability to take on larger acquisitions, while sharing part of the portfolio with other talented operators. In preparations for future deals, Standard Bear REIT had previously engaged in several discussions with Aspen about splitting up the portfolio in a similar way. So when this opportunity came along, the foundation that we had built with Aspen made this a very smooth process. We look forward to working with them and doing additional deals with Aspen and other operators like them. As for the 17 facilities that we will be operating, our local leaders in California, with the support of the Service Center, have been working tirelessly to prepare for this transition. While the transaction is larger than our typical tuck-ins, our locally driven approach to acquisitions allows us to rely on the dozens of CEO caliber leaders we have in these markets to direct the transition of each operation in the same way we execute a one or two building acquisition. We are also extremely grateful to Sabra for their support during this period. We have been so impressed with the Sabra team, and it's truly a pleasure to work with the real estate partners that really get it. We also want to thank North American for their cooperation during this very complicated process. Due to the uniquely public nature of this transaction, we were very grateful to be given early access to these operations during the pre-transition phase. We look forward to working together with the outstanding leaders and teams already in place in these operations to build on the strong clinical and operational reputations they have earned in their communities. As we evaluate growth from last year and since, which including these recent California acquisitions total 46 new operations, we can see that our discipline is paying off. While there were literally several hundred opportunities over the last 12 to 18 months, we remain patient and we're careful to stick to our fundamental growth principles. As with any transition, it will take time for these operations to contribute to the bottom line. However, these operations are coming to us with a solid foundation of clinical and operational strength. And when combined with an infusion of enzyme cultural and operational principles, we are confident that these operations will thrive and become solid contributors to each of their markets and clusters. During the year, Standard Bearer added 10 new real estate operations, all of which will be leased to an Enzyme-affiliated tenant. An Enzyme affiliate entered into 39 new long-term leases with third-party landlords. As this recent activity illustrates, the ratio between leased and owned will vary depending on the circumstances. We are first and foremost focused on the operational health of all our acquisitions. So when it makes sense and pricing is right, we will opportunistically purchase the real estates. But at the same time, when attractive long-term leases come our way, we'll sign those too. And as we've shown over our 23-year history, there will be many opportunities to do both. Looking forward, we are preparing for even more growth in 2023. While we expect the pace of our closing to slow for the coming months, we continue to see a wide range of large, medium-sized, and small portfolios. The past couple of years have been very difficult for skilled nursing operators, and we see evidence of that in low occupancy and high utilization of contract labor and poor clinical and financial health of the facilities that we have recently acquired. As a result, we still expect that there will be lots of opportunities that will arise throughout the year. But as we said before, we will continue to stay true to our strategy of disciplined growth. And with that, I'll turn the call over to Spencer, our COO, to add more color around our operations. Spencer?
spk15: Thanks, Chad. As Barry and Chad have indicated, an important part of our story has been our local leaders' ability to acquire struggling operations and transform them into Ensign caliber operations. Those of you who are familiar with Ensign's history know that our organization was born in challenging times. And our model has proven time and time again that industry challenges present great opportunities to innovate and thrive. While there continues to be significant growth potential in our same store facilities, because of recent acquisition growth, the two facility highlights I want to share today are operations in our transitioning category. These examples illustrate the post acquisition turnaround process that continues to be so fundamental to our long-term success. The first highlight is surprise rehabilitation. located in Phoenix, Arizona metro area. This 100-bed facility was a new build that had been shuttered due to the prior owner's struggles with local licensing and regulatory authorities. And when it was acquired in August of 2019, the facility had no residents and no staff. With the support of our cluster partners and the strong Bandera resource team, CEO Brian Lorenz, COO Heather Rucker, and Executive Director Derek Bowen systematically began building a team that shared their vision. Their vision attracted great healthcare professionals, and soon their senses and reputation were growing. The team worked relentlessly on developing high clinical standards and improving staff competency. As a result, the facility has increased its capacity to successfully treat high-acuity patients, including those needing ventilators and other respiratory care. Despite the challenging acuity, Heather and her team have attained and maintained a five-star overall rating from CMS, as well as a five-star score for quality measures. These clinical accomplishments have been made possible through the surprise team's commitment to creating a unique environment where people want to work. These efforts not only resulted in reduced staff turnover, but also led to less reliance on agency staff. despite being in an extremely competitive labor environment. This employee-centric culture also enabled Surprise Rehab to innovate in ways that would have been impossible for most facilities. For example, in 2021, as healthcare staffing challenges reached a crescendo, the team created a CNA training school that has been recognized as a model throughout Arizona. This program has already produced over 150 new CNAs at Surprise. and has been duplicated by other Ensign affiliates in Arizona to produce over 500 graduates life to date. With its strong quality outcomes and healthy culture, financial outcomes have naturally followed. For example, the facility ended 2020 at 57% occupancy. This number grew to 85% in 2021, and the facility ended 2022 averaging over 95% occupied for the entire year. With high occupancy and skilled clinical staff, the surprise team was able to fine tune their skilled mix, ending Q4 at over 98% skilled days. And as you would expect, total revenues increased and EBIT improved 73% in Q4 2022 over prior year quarter. Growing a facility from zero to 95% occupancy is an impressive feat in normal times, but to do it in the midst of a global pandemic and unprecedented healthcare staffing challenges, it's truly incredible. While the Surprise Rehab highlight demonstrates the incredible outcomes that are possible in a fully transitioned operation, our second facility highlight provides a glimpse into a facility that's at an earlier stage in the transition process. The Oaks at Lakewood is an 80-bed skilled nursing and rehabilitation center located near Tacoma, Washington. Prior to acquisition in mid-2021, This facility was plagued with physical plant issues, a historically poor reputation in its community, low occupancy, and was utilizing large amounts of agency nursing staff. However, Executive Director Casey Bradburn and DON Erlinda Calzado saw the facility's potential and together with their cluster partners began establishing a positive culture and inspiring hope of what the facility could become. While there have been many long, hard days, their diligence and their discipline and doing the right things has started to pay off. Today, the Oaks at Lakewood is rated four stars by CMS and is gaining the respect of the local provider community. Turnover is down markedly from 2021 levels, and during the last two quarters, the facility has not utilized a single shift of agency labor, despite occupancy improving from 79% in Q4 of 2021 to 86% in the fourth quarter. with skilled Medicare days improving by 91% during that same period. This occupancy growth has translated to a 27% revenue increase for Q4 2022 over prior year quarter, and because of the facility's success in eliminating costly agency staff, EBIT has improved 56% over Q4 2021. While acquisitions are difficult and they require significant investment from our local operators, These two examples demonstrate just how rewarding the work can be. We hope that these examples help illustrate some of the many different levers that our local operators are pulling in order to meet the needs of their healthcare continuum partners. With that, I'll turn the time over to Suzanne to provide more detail on the company's financial performance and our guidance. Suzanne?
spk12: Thank you, Spencer, and good morning, everyone. Detailed financials for the quarter and year are contained in our 10-K and press release filed yesterday. Some additional highlights include the following for the year. GAAP diluted earnings per share was $3.95, representing an increase of 15.5%. An adjusted diluted earnings per share was $4.14, an increase of 13.7%. Consolidated GAAP revenues and adjusted revenues were both 3.4%. an increase of 15.1%. GAAP net income was $224.7 million, an increase of 15.4%. An adjusted net income was $235.7 million, an increase of 13.8%. For the quarter, GAAP diluted earnings per share was $1.06, an increase of 23.3%. An adjusted diluted earnings per share was $1.10, an increase of 13.4%. GAAP net income was $60.5 million, an increase of 24.1%. And adjusted net income was $62.7 million, an increase of 14.1%. Other key metrics as of December 31st include cash and cash equivalents of $316.3 million, cash flow from operations of $272.5 million, and $593 million of availability on a revolving line of credit. We continue to provide additional disclosure on Standard Bear, which is now comprised of 103 properties owned by the company and are leased to 75 affiliated skilled nursing and senior living operations, as well as 29 which are senior living operations that are leased to the Pennant Group. Each of these properties is subject to triple net long-term leases and generated rental revenues of $19.4 million for the quarter, of which $15.6 million was derived from the Enzyme-affiliated operations. Also, Standard Rare produced $13 million in FFO and had an EBITDA to rent coverage ratio of 2.4 times. We continue to deliver our portfolio, achieving a lease-adjusted net debt to EBITDA ratio of 1.98 times, a decrease of 2.13 times from last year. We also own 108 assets, 84 of which are unlevered, with significant equity value that provide us with even more liquidity. During the quarter, we increased our cash dividends to 5.75 cents per share for the 20th consecutive annual dividend increase. Given our strength, we plan to continue our 20-year history of paying dividends into the future. We also want to address the current status of the state of emergency and reimbursement matters. Recently, HHS extended the public health emergency for another 90 days. Separately, enhanced FMAP funding was approved and will be stepped down through 2023. Additionally, the White House has made several comments that it intends to end the PHE on May 11, 2023. As Barry mentioned, we are providing our annual earnings guidance of $4.60 to $4.74 per diluted share, and annual revenue guidance of $3.55 billion to $3.62 billion. We have evaluated multiple scenarios, and based on the strength in our performance and the positive momentum we've seen in occupancy and strong skilled mix, as well as some additional strengths in Medicaid and managed care programs, it gives us confidence that we will be able to achieve these results. Our 2023 guidance is based on diluted weighted average common shares outstanding of approximately $57.7 million, a tax rate of 25%, the inclusion of acquisitions anticipated to close in the first quarter of 2023, the inclusion of management expectations for FMAP grants, Medicare and Medicaid funding, and reimbursement rates net of provider tax, with the primary exclusion coming from stock-based compensation. Other additional factors that could impact quarterly performance include variations in reimbursement systems, delays and changes in state budgets, seasonality and occupancy and skilled mix, the influence of the general economy and census and staffing, the short-term impact of our acquisition activities, variations in insurance calls, surges in COVID-19 and other factors. And with that, I'll turn it over to Barry. Barry?
spk08: Thanks, Suzanne. We want to again thank everyone for joining us today and express our appreciation to our shareholders for their confidence and support. We know that this year will be not without some unique challenges. However, we're encouraged by our operational strength and our core business. As always, we want to recognize our talented field leaders for their heroic efforts, along with those of our nurses, therapists, and other frontline care providers who continue to provide an industry-leading example of life-enriching service to our residents, coworkers, and our communities. We're also appreciative to our colleagues at the service center who are working tirelessly to support our operations, enabling us to succeed in spite of the challenges we faced. Thank you for making us better every day. We'll now turn over to the Q&A portion of our call. Carmen, can you please instruct the audience on the Q&A procedure?
spk10: Thank you. And as a reminder, To ask a question, simply press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press the star 11 again.
spk09: Please stand by while we compile the Q&A roster. And it comes from the line of Ben Hendrix with RBC Capital Markets.
spk10: Your line is open.
spk04: Hey guys, thank you very much. I just wanted to ask about your skilled mix momentum. Clearly we're seeing evidence of your higher acuity capabilities, but also some COVID and respiratory impacts in there as well. How should we think about steady state mix for your same store portfolio? And then from a modeling standpoint, how should we think about skilled mix evolving through the year? Thank you.
spk08: Yeah, I'll just, I'll speak generally about it and let Suzanne fill you in on any other insights she has. But, um, You know, as we compare kind of where we are today from a skilled mix standpoint to where we were both last quarter and last year, and even pre-COVID, we are pretty confident in the strength that we're building and the momentum that we're building in our ability to continue up the acuity chain and attract customers sicker patients, which is ultimately the goal. To be the best resource for our hospitals and managed care partners is always at the forefront of what we're thinking, and that means an evolution towards being nimble and adaptive to what their needs are, and their needs include ensuring that we have the capability to care for a more acute patient. So, you know, as we look at the impact of COVID this quarter, certainly it was a little bit higher than the same quarter last year. But comparable to kind of where we were last quarter, you know, what we see is that, you know, even though there was more COVID activity this quarter than there was in the same quarter last year, it's not much. And so... What that indicates to us is on a steady state basis, even in quarters where we're not really impacted by COVID, we're still fundamentally higher than where we were kind of going into this pandemic. And that momentum just, you know, it just continues. And so we're encouraged by that. Anything you want to add to that, Suzanne?
spk12: No, I think you said it really well. I think one of the things that we've been noticing for the last couple of quarters is a little bit less dependence on the waivers and maybe that COVID and our skilled mix isn't as aligned. And so I think as Barry mentioned, I think we're really excited for where we are and the relationships that we've made throughout the entire year with our managed care partners continue to be strong. And as we continue to see that portion of the skilled mix build,
spk04: Thank you. Just a quick follow-up. You've noted that states have been supportive of the PHE roll-off and the soft landing there, but is there any cadence, quarterly cadence considerations we need to be thinking about as we think about the second half of the year? Thanks.
spk12: Yeah, great question. Obviously, we have the announcement out there on the end of the PHE with the White House then leaning towards that May date. And so as we kind of look through that, you know, we're planning on getting some additional funding through that May date from the states that have been supportive. And as we've talked on previous calls, just a reminder, that was California, Arizona, and Texas. I think on the last call we talked about that California really has broken away from tying anything to the state of emergency. So they've really said that they're going to be supportive for the remainder of the year. So I feel great about California. Arizona has really thought through this good and well as they look to put the dollars in more into the rate. And so we've already started to see some of that come through in Arizona. And then Texas, I think, is the last one out there. They've kind of done a couple of things. They've looked at the the PHE, but they've also done some grants that we're expecting to see come in through the year. And then as we've talked to you guys about, there's that potential that we would have a hole between kind of when the state of emergency and the grants may not cover to the beginning of September. So I feel pretty good about how the states are lining up, what it's going to be a mix of kind of, you know, continued FMAP funding, additional rate funding, and then some of these grant programs that we've seen the states put in place. Barry, what did I miss?
spk08: I think that's it, Ben. I mean, ultimately, you know, I think as our guidance indicates, we feel pretty strong about, even though there are some small unknowns from state to state, overall, I think we feel like there's a pretty clear pathway for us to not have some massive blips on the state reimbursement front as FMAP fades. And like we mentioned earlier, it doesn't really just go away. It steps down. And so even with that step down, if there were no, like say it wasn't a bridge in Texas, for example, I don't think that would impact our outlook for the year at all.
spk05: That's great, guys. Thank you.
spk07: thank you one moment for our next question please and it comes from the line of koq with steve l please proceed hey good morning everyone uh congrats on closing the north american transaction um so barry you know i really appreciate the comment on the performance of the legend portfolio so on the uh north american assets I think Cyber has reported that their EBITDA rent coverage for these assets have been about 1.0 times. So it sounds like these should be created on day one. Are these California assets different from Legend or your typical turnaround opportunities if you look at them from either occupancy, skill mix, or cost saving potentials? And how long do you think it would take you to get your stabilization? And as a follow-up, could you also comment on the leadership pipeline and the current capacity to take on more assets?
spk08: Yeah, that's great questions, Tal. So, you know, this portfolio is an excellent one. It's one we've, you know, there was an opportunity to look at it a few years back. We were excited about it then. We know these buildings, they're buildings that we have competed with in the past. They're buildings that we have relationships with some of the leaders. And so we're really excited about this portfolio. We think it'll be a great addition. I will say this, not just about North America, but about transitions we're seeing in general. Given the labor challenges just globally, most buildings, and these are no exception, have high amounts of agency labor usage. And so more than obviously typical, as we're seeing ourselves. But these in particular have quite a bit. And so again, like with some of the recent ones we've taken on, the pathway for kind of a traditional recovery is somewhat hampered there. Getting agency out of a building in an environment like now is much more difficult, as you can imagine. So that's one of the primary challenges that we're facing is just to get to where we like to be as quick as we need to be is going to be challenged by the current state of labor. That said, these buildings are in really good condition clinically and have really good culture overall. I've been able to visit a few already. I've gotten to know some of the leaders of these buildings and some of the clinicians. And given the clinical stability that exists there, I think that provides us somewhat of an advantage for us to not say it's going to take forever. But it will take some time regardless. in spite of that. But again, like we mentioned in our prepared remarks, we take a long-term approach to these. We're not afraid of that challenge that exists. But we're going to go about it methodically and do it the right way. The other thing I'll mention, too, is just from an occupancy standpoint, the portfolio that we're taking on sits in the low 80s in terms of percentage. For California, that's pretty low. So that will be another lever we're going to be focused on. And then just some other cost issues that we should be able to tackle more readily. But that all said, I don't think we're bullish enough to say these will be accretive this year, but one never knows. Hopefully the transition goes smoother than we hope it will, but we're planning on it being You know, in spite of all the challenges I've mentioned, we're anticipating these will be kind of on our normal cadence of being successful over the next few quarters.
spk16: Leadership.
spk08: From a leadership pipeline perspective, Tao, you know, we have a really strong stable of what we call administrators in training or CEOs in training. It's as strong as it's ever been, in spite of the fact that unemployment's pretty low. And that's a really good sign. We probably will be a little more tempered in our path of growth as we digest these 35 or so buildings we've taken in the last six months, as we have been in the past. But we actually, in spite of that, are geared to be able to take on... many more buildings, especially in other geographies where we haven't been as acquisitive lately. So we'll see. We'll be opportunistic, and we'll take a tempered approach to that. But we obviously will have more growth this year for sure. But it will probably come more in the latter half than in the next few months.
spk07: Yeah, thanks for the color there. My second question is, we noticed that the DSO ticked up a little bit sequentially. I think we also saw that in your 10-K, you updated the risk disclosure around the growth of the Medicaid managed care organizations and the potential delay or reduction in Medicare reimbursement. Just curious if you have any general observations about the billing and collection trend for managed care in general. Anything worth calling out there?
spk12: Yeah, great question, and a couple of different aspects to that. Obviously, in the current quarter, for Q4, we had a lot of acquisitions. And so what we talk about, and just want to remind people, during stages of heavy acquisitions, our anticipated collections will be slower. That is just a normal part of doing acquisitions as we go through the change in ownership process and transfers everything over. you know, as we kind of look for fourth quarter, it was just a little bit slower in the normal basis as well. And that really had to do with a lot of managed care organizations and a couple of states playing a little bit slower than that they normally do at the end of the year. With regards to the risk factor, what we added on, we did, you know, just want to highlight that there are more and more states that are changing from a direct pay system to a managed care system. So Now almost all of our large states are all in managed Medicaid states. When the program goes from just a regular direct pay to managed Medicaid, the payments do come slower to us. And so one of our big states, California, switched in 2023 to that. And so we just want to give people a heads up that we'd expect some slowdown in our Medicaid collections in the state of California due to that transition.
spk07: Got you. And a final question, if I may, you know, if I look at the balance sheet, right, obviously that's under leveraged and you have abundant equity and very strong cash flow. You know, we're forecasting somewhere around $300 million operating cash flow and really $200 million free cash flow for the next two years. You know, just curious in terms of capital allocations, what are the things that you would prioritize? You know, I know that you have raised the dividend. You had a stock repurchase program last year. you know, how should we think about where you would allocate capital?
spk03: Yeah, Tal, I can take that as a chat. Certainly acquisitions would be the top of our list. You know, we see ourselves very much in growth mode and will continue to be. You know, and then obviously, you know, CapEx on the physical plants is another big spend, right? And, you know, one note on the cash flows too, you know, when we have larger, heavier periods of acquisition like we have over the last, you know, six months, that can tend to have a little bit of a drag on our cash flows as we see AR climb a little bit with just the nature of licensing and, you know, it's just part of kind of the process of a transition from one operator to another. So that will actually, you know, probably impact our cash flow a little bit. I think you'll see that. As we talked about a lot, we keep our balance sheet the way it is so that we can be ready when great opportunities arise. As I said in my prepared part of the script, I think we expect to see additional opportunities coming up this year and next. And we want to be prepared for that. So that's how we kind of look at the balance sheet.
spk12: And prepare both on the operating front as well as the standard bear rate front. So I think as we kind of look at that multifaceted ability to acquire, that would definitely be our number one use of those flows.
spk06: Great. Thank you for taking my questions.
spk10: Thank you. One moment for our next question, please. And it comes from the line of Scott Fidel with Stephens. Please go ahead.
spk13: Thanks. And hi, everyone. Actually, just wanted to pick that right up on that last topic just around operating cash flow. maybe get a little more visibility into what you're building into your outlook for next year. You've been running in that $275 million area for the last two years, and then you've talked about in the near term having some of these dynamics just around the acquisitions. Is it reasonable to think about operating cash flow stepping up a bit in 2023, just given the larger revenue scale, or are you assuming it remaining relatively stable with where it's been trending the last two years? then also what you're modeling for CapEx as well.
spk12: Yeah, great question, Scott. I think the one thing when you're looking at cash flows and you kind of think through the number of acquisitions that we've done, you know, our states can vary between four months and 18 months is the longest transition that we've ever had as they've got us on. And so as you kind of think through where those cash flows go, we try to try to normalize it all and hope that they all come in, you know, kind of in the middle of that realm. And then after we get that licensing process done, then we have to go through the managed care process and get them recredentialed through their new license under managed care. So that's a secondary step. And again, that can take, you know, two to six months on top of that after you've already waited. And so It's a little bit of a waiting game, and so that's why we kind of, as you listen to Chad, of use of cash, one of the things that we'll probably end up having to do is use some of that working capital to get us through those CHOW processes. Now, our hope, and we have great systems and great processes, that it goes very succinctly, and we're on the early end of that. But unfortunately, we are at each individual state government's processing timeline a little bit here. with regards to how quickly it goes through. So, I think it wouldn't be unreasonable to say, you know, we would expect kind of that same flow net-net, because AR will grow.
spk03: Just a little bit there. California tends to be one of the slower states, too. Texas is faster than California, and so that's why it'll probably be a little more pronounced with this particular set of deals as well.
spk12: Right, and definitely different states have different things they turn off immediately. So Texas turns a lot more stuff off immediately, and so we get not a dollar in the door. In California, there's a little bit, we get some cash in the door quick, and then we have a turnoff period, and then it goes back on. So every state, again, we're talking super nuanced here, so a little bit up and down there.
spk08: We haven't talked a whole lot very recently about standard bearer, but we have been preparing for this and are still thinking a great deal about opportunities for standard bearer. Having cash availability for deals that, again, may not fit our operating footprint, but might be good real estate opportunities or something we always want to be ready for as well. Not signaling that we have anything in the works necessarily, but, you know, we have great hopes for Standard Bear to have some opportunities as well for growth.
spk13: Understood. And certainly you have a tremendous amount of liquidity, but as we're just sort of honing in on trying to model the operating cash flow correctly, is it Maybe it's reasonable for us to think about those four Q dynamics persisting over the next quarter or two, and then you sort of get more of that cash flow normalization in the back half of the year. Do you think that's sort of a reasonable baseline assumption?
spk12: I think that's a reasonable baseline assumption, knowing that we did just as much in Q1 as we did in Q4. And so I think it's a reasonable baseline. And then we can update you guys throughout the year, as we always do, as you see the cash come in, or if we see someone extending with regards to the timing of the licensing process, which would make it last longer, or if they tighten up and they do a great job at the states, then you won't see it as pronounced in the cash flows.
spk13: Got it. And then just my second question. Just interested if you could give us an update on your managed care contracting for 2023 and how you've seen your managed care rate trends sort of playing out relative to some of the inflationary dynamics. And then just interested, too, if you've had a chance, I'm sure you've started this for sure, to just dig into the managed care contracting at the North American facilities and whether you see opportunities, you know, to improve the the managed care rates, you know, as you try to drive synergies off of those acquired properties.
spk12: Another great question. I think when you think through the dynamics that we have, you know, we do have some of our larger contracts that we feel really good about, that they have recognition that labor has increased and overall cost has increased. And so we have At least one MCO provider who's actually recognized that. I think a lot of the other MCOs are looking and still struggling with regards to our overall cost increasing. And so they're kind of at their historical rates as a starting point, you know, anywhere between 2% and 3% as a starting point. But as we try to demonstrate to them the cost increases that we have had, I think that's the beginning of the negotiation. And so we've had some really good success with a few. There are some that are a little bit more holdout. So I think some of that progress and the negotiation time might go on a little bit longer because where we're asking for rates to increase is higher than they've historically done. And again, we've been very successful with some of the larger ones. And remember, we don't have For the most part, we don't have one contract that covers the entire company, but we really have a lot of smaller contracts so that what happens is we'll get wins throughout the year, and then that'll kind of come in over the entire period of the year.
spk14: Okay. All right, great. Okay, thanks.
spk10: Thank you. And with that, we end our Q&A session for today. I would like to turn the conference back to Mr. Barry Port for his closing remarks.
spk08: Thank you, everyone, for joining us today, and we look forward to a great year.
spk10: Thank you. And this concludes today's conference call.
spk09: Thank you for participating, and you may now disconnect.
spk10: The conference will begin shortly. To raise and lower your hand during Q&A, you can dial star 11. Thank you. Thank you. you Thank you. Thank you.
spk00: Thank you. you
spk10: Good day and thank you for standing by. Welcome to the Ensign Group Inc. 4th Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automatic message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I will now hand the conference over to Mr. Kitch.
spk02: Thank you and welcome, everyone, and thank you for joining us today.
spk03: We filed our earnings press release yesterday, and it is available on the investor relations section of our website at nzinegroup.net. A replay of this call will also be available on our website until 5 p.m. Pacific on Friday, March 3rd, 2023. We want to remind any listeners that may be listening to a replay of this call that all statements are made as of today, February 3rd, 2023, and these statements have not been nor will be updated subsequent to today's call. Also, any forward-looking statements made today are based on management's current expectations, assumptions, and beliefs about our business and the environment in which we operate. These statements are subject to risks and uncertainties that could cause our actual results to materially differ from those expressed or implied on today's call. Listeners should not place undue reliance on forward-looking statements and are encouraged to review our SEC filings for a more complete discussion of factors that could impact our results. Except as required by federal securities laws, Enzyme and its affiliates do not undertake to publicly update or revise any forward-looking statements where changes arise as a result of new information, future events, changing circumstances, or for any other reason. In addition, the Enzyme Group, Inc. is a holding company with no direct operating assets, employees, or revenues. Certain of our wholly owned independent subsidiaries, collectively referred to as a service center, provide accounting, payroll, human resources, information technology, legal, risk management, and other services to the other operating subsidiaries through contractual relationships with such subsidiaries. In addition, our wholly owned captive insurance subsidiary, which we refer to as the insurance captive, provides certain claims-made coverage to our operating companies for general and professional liability, as well as for workers' compensation insurance liabilities. Enzyme also owns Standard Bear Healthcare REIT, Inc., which is a captive real estate investment trust that invests in healthcare properties and enters into lease agreements with certain independent subsidiaries of Enzyme, as well as third-party tenants that are unaffiliated with the Enzyme group. The words Ensign, Company, We, Our, and Us refer to the Ensign Group, Inc. and its consolidated subsidiaries. All of our operating subsidiaries, the Service Center, Standard Bearer, Healthcare REIT, and the Insurance Captive are all operated by separate, wholly owned, independent companies that have their own management employees and assets. References herein to the consolidated company and its assets and activities, as well as use of the terms We, Us, Our, and similar terms we may use today are not meant to apply, nor should it be construed as meaning that the Enzyme Group has direct operating assets, employees, or revenue, or that any of the subsidiaries are operated by the Enzyme Group. Also, we supplement our GAAP reporting with non-GAAP metrics. When viewed together with our GAAP results, we believe that these measures can provide a more complete understanding of our business, but they should not be relied upon to the exclusion of GAAP reports. A GAAP to non-GAAP reconciliation is available in yesterday's press release and is available in our Form 10-K. And with that, I'll turn the call over to Barry Port, our CEO. Barry?
spk08: Thank you, Chad, and thank you for joining us today. We were pleased to announce yesterday another record quarter. These results demonstrate yet again that our local leaders and their teams continue to be the examples of post-acute excellence as they wade through the evolving landscape in each of their markets. They have again achieved record results in spite of the continued disruption in the labor markets. Remarkably, we saw continued improvement in occupancies, skilled revenue, and managed care revenues. We were particularly pleased that we achieved sequential growth in overall occupancy for the eighth consecutive quarter, with same-store and transitioning operations increasing by 2.9% and 4.3%, respectively, over the prior year quarter. As of the end of the quarter, our same-store occupancy reached 77.8%, and we continue to get closer to our pre-COVID occupancy levels, which was at 80.1% in March of 2020. We are amazed by the commitment of our caregivers and their continued endurance and strength. We've also been very pleased with the progress we've made in improving our skilled mix. As those that have followed us know, growth in skilled mix only happens after our local teams demonstrate over and over that they can achieve successful outcomes for sicker patients that need more advanced care. During the quarter, our same-store operations grew their skilled mix revenue by 9.1% over the prior year quarter. Additionally, in the wake of the pandemic, there's been a lot of noise around potential shifts to home-based care or lack of support for inpatient post-acute services from hospitals and managed care providers. But when compared to pre-COVID levels, our skilled mix has remained elevated, showing just how important high-quality post-acute services are within the continuum of care. We've always been confident that our skilled mix would continue to be strong, but we are very pleased to see this continuous fundamental growth in skilled mix as it demonstrates the increasing and sustainable demand for skilled post-acute services without a significant impact from COVID. We continue to be impacted by the labor environment, but we are very encouraged by the improvement in several key internal performance areas that show that these issues are stabilizing. For example, we continue to see the rate of wage inflation slowing down, as we've experienced two quarters in a row of slower wage growth. In addition, while our use of agency labor is still higher than we'd like it to be, we are encouraged to see several markets becoming less and less reliant on agency labor. In addition, we also expect that as wage inflation moderates that our need for agency labor will also continue to decrease. Lastly, we are also very pleased to see improvements in our employee turnover due to our leaders' relentless effort to create an employee-focused culture that aligns with our collective core values. Recently, the federal government extended the state of emergency to April 2023, which keeps in place many of the regulatory and other reforms of assistance helpful to patient care. Additionally, the government has indicated that the PHE will end in May of 2023. We also continue to benefit from FMAP-bolstered Medicaid funding in several states. some of which will end or phase out throughout the year. However, this federally supported funding will be replaced in large part with appropriate state-based funding, ensuring a relatively smooth transition. In addition to occupancy growth and continued skilled mix improvement, one major aspect of our company's resilience has been and continues to be our local leaders' ability to acquire struggling operations, and transform them into facilities of choice for their communities. This ability combined with a strong balance sheet allows to increase the number of acquisitions we do in times of uncertainty when many operators are choosing or being forced to exit the industry. With the 17 acquisitions that we completed on February 1st, we have now added 37 affiliated operations since July 1st, 2022. We remain confident that our operating model will continue to allow each operator to form their own market-specific strategy and adjust to the needs of their local medical communities, including methods for attracting new healthcare professionals into our workforce and retaining and developing existing staff. These transitions will take time, particularly given the higher than normal reliance on agency staffing prior to the acquisition. But with each new operation, we are creating new opportunities for the next generation of leaders and look forward to working together to help each operation reach its enormous clinical and financial potential. I want to speak briefly about our ability to execute on the acquisition of a larger portfolio. In November, we announced that we had agreed to acquire 20 California buildings that have been operated by North American Healthcare, 17 of which we will operate. Just two days ago, we closed the transaction and we're very excited and encouraged with how things have gone so far. Over the last few months, we've had several investors ask us about our ability to execute on larger acquisitions while reminding us that the last larger deal we closed was the Legend transaction in Texas, which was a similar size. Those that were following us back in 2016 will remember that the legend transaction took several quarters to produce the results we expected. We were very open about the lessons we learned that made that transition a little more challenging than we anticipated. But as we look back, we worry we haven't done a good enough job at telling the massive success story that the legend operations have become. Those operations have been contributing a significant amount to our earnings for several years now and are currently achieving at least the EBITDA coverage of 2.1 times. To give an even clearer picture, the EBITDA growth from acquisition until the end of 2022 has increased by over 160%. We certainly made some missteps early on in our approach to the legend acquisition, but even with those short-term setbacks, We would not be as strong as we are today in Texas without them and would definitely do that deal over and over again. I point to this example not to suggest that we expect the exact same results in this new portfolio. I do so only to underline how we look at acquisitions, including larger portfolios. We never acquire something for its short-term impact. We acquire a single building or 17 if and when we see significant opportunity create lasting long-term value to our portfolio. For the last several months, we have been preparing for these additions and have been implementing lessons learned in 2016 and 2017. All transitions take time, and we expect these will be no different, but we are thrilled and grateful to have the opportunity to work together with our new partners in this California portfolio, as well as the other geographies. and look forward to the contribution they will make to this organization over the next 20 years. As we evaluate our expanding portfolio, we see more organic growth potential within our existing portfolio than ever before. As we relentlessly follow and protect the cultural fundamentals that got us here, we are confident that we will continue to consistently produce world-class clinical and financial performance. We are very humbled by what we were able to accomplish in 2022 while dealing with so many unusual challenges. But we also know we can still do much better and are excited about the potential within our portfolio as we continue to apply our proven, locally-driven healthcare model. We are issuing our annual 2023 earnings guidance of $4.60 to $4.74 per diluted share and annual revenue guidance of $3.55 billion to $3.62 billion. The midpoint of this 2023 earnings guidance represents an increase of 12.8% over our 2022 results and is 28.3% higher than our 2021 results. We are excited about the upcoming year and are confident that our partners will continue to manage and innovate through all of the lingering challenges on the labor front And when we consider the current health of our organization combined with our culture and proven local leadership strategy, we feel we are well positioned to have another outstanding year in 2023. Next, I'll ask Chad to discuss our recent growth. Chad?
spk03: Thank you, Barry. As we expected, we continue to add to our growing portfolio and are very excited about the 12 new operations we added during the quarter. These newly acquired operations include three skilled nursing operations in South Carolina, one skilled nursing operation in Arizona, six skilled nursing operations in Texas, and two skilled nursing operations in Colorado, totaling an additional 1,505 new operational beds. We always place the highest priority on growth opportunities within our existing footprint and are very excited about the addition to some of our most mature markets like Arizona and Colorado. Each of these operations were very carefully selected and will bolster our ability to fulfill the needs of our healthcare partners in geographies we didn't previously, or it simply enhances our service offerings in markets we have been in for years. We are also particularly excited about completing our first set of acquisitions in South Carolina since we entered that state several years ago. As we said before, entering new states is challenging and can often take time to gain the trust of the local healthcare community. Each of these operations in South Carolina is off to a great start. and we hope that we will be able to continue to build the Enzyme footprint in the Mid-Atlantic region. In addition, we also completed the previously announced acquisition of 20 skilled nursing operations in the state of California that have been operated by North American Healthcare. The real estate assets are all owned by Sabra Healthcare REIT and have been added to our long-term triple net master lease with them. As we said when we announced this transaction last November, We are honored that Sabra will be entrusting us with the operation of this portfolio and are very excited to expand our growing relationship with them. These California operations are a perfect fit with our existing footprint in some of our strongest and most mature markets, as well as giving us an opportunity to move into the Bay Area. As we evaluated the size and scope of the 20-building portfolio, there were three operations located in the Sacramento area that were geographic outliers for us. In addition, given the size and scope of the remaining 17 operations and the amount of resources that are necessary to transition that many operations at one time, we determined that the best course of action was to partner with another like-minded operator on those three operations. So as of February 1st, and with Sabra's consent, we entered into a sublease for the three Sacramento operations with Aspen Healthcare. In total, Enzyme Affiliates will operate 17 of the 20 buildings. adding 1,462 operational beds to Enzyme's portfolio, and Aspen will operate three of the 20 buildings, representing 245 operational beds. Just a side note, these subleased operations will not contribute to our overall performance. Aspen is a very reputable operator that currently operates 34 skilled nursing facilities in We have enormous respect for Aspen as an operator and believe that they are in a great position to build on the quality reputation these buildings already enjoy. They also have a strong balance sheet and have provided a company-level guarantee of their obligations under the sublease. As an aside, while this is not a situation where we own the real estate, as we've discussed for some time now, part of our strategy with our internal REIT is to expand our ability to take on larger acquisitions, while sharing part of the portfolio with other talented operators. In preparations for future deals, Standard Bear REIT had previously engaged in several discussions with Aspen about splitting up the portfolio in a similar way. So when this opportunity came along, the foundation that we had built with Aspen made this a very smooth process. We look forward to working with them and doing additional deals with Aspen and other operators like them. As for the 17 facilities that we will be operating, our local leaders in California, with the support of the Service Center, have been working tirelessly to prepare for this transition. While the transaction is larger than our typical tuck-ins, our locally driven approach to acquisitions allows us to rely on the dozens of CEO caliber leaders we have in these markets to direct the transition of each operation in the same way we execute a one or two building acquisition. We are also extremely grateful to Sabra for their support during this period. We have been so impressed with the Sabra team, and it's truly a pleasure to work with real estate partners that really get it. We also want to thank North American for their cooperation during this very complicated process. Due to the uniquely public nature of this transaction, we were very grateful to be given early access to these operations during the pre-transition phase. We look forward to working together with the outstanding leaders and teams already in place in these operations to build on the strong clinical and operational reputations they have earned in their communities. As we evaluate growth from last year and since, which including these recent California acquisitions total 46 new operations, we can see that our discipline is paying off. While there were literally several hundred opportunities over the last 12 to 18 months, we remain patient and we're careful to stick to our fundamental growth principles. As with any transition, it will take time for these operations to contribute to the bottom line. However, these operations are coming to us with a solid foundation of clinical and operational strength. And when combined with an infusion of enzyme cultural and operational principles, we are confident that these operations will thrive and become solid contributors to each of their markets and clusters. During the year, Standard Bearer added 10 new real estate operations, all of which will be leased to an Enzyme-affiliated tenant. And Enzyme affiliates entered into 39 new long-term leases with third-party landlords. As this recent activity illustrates, the ratio between leased and owned will vary depending on the circumstances. We are first and foremost focused on the operational health of all our acquisitions. So when it makes sense and pricing is right, we will opportunistically purchase the real estate. But at the same time, when attractive long-term leases come our way, we'll sign those too. And as we've shown over our 23-year history, there will be many opportunities to do both. Looking forward, we are preparing for even more growth in 2023. While we expect the pace of our closing to slow for the coming months, we continue to see a wide range of large, medium-sized, and small portfolios. The past couple of years have been very difficult for skilled nursing operators, and we see evidence of that in low occupancy and high utilization of contract labor and poor clinical and financial health of the facilities that we have recently acquired. As a result, we still expect that there will be lots of opportunities that will arise throughout the year. But as we said before, we will continue to stay true to our strategy of disciplined growth. And with that, I'll turn the call over to Spencer, our COO, to add more color around our operations. Spencer?
spk15: Thanks, Chad. As Barry and Chad have indicated, an important part of our story has been our local leaders' ability to acquire struggling operations and transform them into Ensign caliber operations. Those of you who are familiar with Ensign's history know that our organization was born in challenging times. And our model has proven time and time again that industry challenges present great opportunities to innovate and thrive. While there continues to be significant growth potential in our same store facilities, because of recent acquisition growth, the two facility highlights I want to share today are operations in our transitioning category. These examples illustrate the post acquisition turnaround process that continues to be so fundamental to our long-term success. The first highlight is surprise rehabilitation. located in Phoenix, Arizona metro area. This 100-bed facility was a new build that had been shuttered due to the prior owner's struggles with local licensing and regulatory authorities. And when it was acquired in August of 2019, the facility had no residents and no staff. With the support of our cluster partners and the strong Bandera resource team, CEO Brian Lorenz, COO Heather Rucker, and Executive Director Derek Bowen systematically began building a team that shared their vision. Their vision attracted great healthcare professionals, and soon their senses and reputation were growing. The team worked relentlessly on developing high clinical standards and improving staff competency. As a result, the facility has increased its capacity to successfully treat high-acuity patients, including those needing ventilators and other respiratory care. Despite the challenging acuity, Heather and her team have attained and maintained a five-star overall rating from CMS, as well as a five-star score for quality measures. These clinical accomplishments have been made possible through the surprise team's commitment to creating a unique environment where people want to work. These efforts not only resulted in reduced staff turnover, but also led to less reliance on agency staff. despite being in an extremely competitive labor environment. This employee-centric culture also enabled Surprise Rehab to innovate in ways that would have been impossible for most facilities. For example, in 2021, as healthcare staffing challenges reached a crescendo, the team created a CNA training school that has been recognized as a model throughout Arizona. This program has already produced over 150 new CNAs at Surprise, and has been duplicated by other Ensign affiliates in Arizona to produce over 500 graduates life to date. With its strong quality outcomes and healthy culture, financial outcomes have naturally followed. For example, the facility ended 2020 at 57% occupancy. This number grew to 85% in 2021, and the facility ended 2022 averaging over 95% occupied for the entire year. With high occupancy and skilled clinical staff, the surprise team was able to fine tune their skilled mix, ending Q4 at over 98% skilled days. And as you would expect, total revenues increased and EBIT improved 73% in Q4 2022 over prior year quarter. Growing a facility from zero to 95% occupancy is an impressive feat in normal times, but to do it in the midst of a global pandemic and unprecedented healthcare staffing challenges, it's truly incredible. While the surprise rehab highlight demonstrates the incredible outcomes that are possible in a fully transitioned operation, our second facility highlight provides a glimpse into a facility that's at an earlier stage in the transition process. The Oaks at Lakewood is an 80-bed skilled nursing and rehabilitation center located near Tacoma, Washington. Prior to acquisition in mid-2021, This facility was plagued with physical plant issues, a historically poor reputation in its community, low occupancy, and was utilizing large amounts of agency nursing staff. However, Executive Director Casey Bradburn and DON Erlinda Calzado saw the facility's potential and together with their cluster partners began establishing a positive culture and inspiring hope of what the facility could become. While there have been many long, hard days, their diligence and their discipline and doing the right things has started to pay off. Today, the Oaks at Lakewood is rated four stars by CMS and is gaining the respect of the local provider community. Turnover is down markedly from 2021 levels, and during the last two quarters, the facility has not utilized a single shift of agency labor, despite occupancy improving from 79% in Q4 of 2021 to 86% in the fourth quarter. with skilled Medicare days improving by 91% during that same period. This occupancy growth has translated to a 27% revenue increase for Q4 2022 over prior year quarter, and because of the facility's success in eliminating costly agency staff, EBIT has improved 56% over Q4 2021. While acquisitions are difficult and they require significant investment from our local operators, These two examples demonstrate just how rewarding the work can be. We hope that these examples help illustrate some of the many different levers that our local operators are pulling in order to meet the needs of their healthcare continuum partners. With that, I'll turn the time over to Suzanne to provide more detail on the company's financial performance and our guidance. Suzanne?
spk12: Thank you, Spencer, and good morning, everyone. Detailed financials for the quarter and year are contained in our 10-K and press release filed yesterday. Some additional highlights include the following for the year. GAAP diluted earnings per share was $3.95, representing an increase of 15.5%. An adjusted diluted earnings per share was $4.14, an increase of 13.7%. Consolidated GAAP revenues and adjusted revenues were both 3.4%. an increase of 15.1%. GAAP net income was $224.7 million, an increase of 15.4%. An adjusted net income was $235.7 million, an increase of 13.8%. For the quarter, GAAP diluted earnings per share was $1.06, an increase of 23.3%. An adjusted diluted earnings per share was $1.10, an increase of 13.4%. GAAP net income was $60.5 million, an increase of 24.1%. And adjusted net income was $62.7 million, an increase of 14.1%. Other key metrics as of December 31st include cash and cash equivalents of $316.3 million, cash flow from operations of $272.5 million, and $593 million of availability on a revolving line of credit. We continue to provide additional disclosure on Standard Bear, which is now comprised of 103 properties owned by the company and are leased to 75 affiliated skilled nursing and senior living operations, as well as 29 which are senior living operations that are leased to the Pennant Group. Each of these properties is subject to triple net long-term leases and generated rental revenues of $19.4 million for the quarter, of which $15.6 million was derived from the Enzyme-affiliated operations. Also, Standard Rare produced $13 million in FFO and had an EBITDA to rent coverage ratio of 2.4 times. We continue to deliver our portfolio, achieving a lease-adjusted net debt to EBITDA ratio of 1.98 times, a decrease of 2.13 times from last year. We also own 108 assets, 84 of which are unlevered, with significant equity value that provide us with even more liquidity. During the quarter, we increased our cash dividends to 5.75 cents per share for the 20th consecutive annual dividend increase. Given our strength, we plan to continue our 20-year history of paying dividends into the future. We also want to address the current status of the state of emergency and reimbursement matters. Recently, HHS extended the public health emergency for another 90 days. Separately, enhanced FMAP funding was approved and will be stepped down through 2023. Additionally, the White House has made several comments that it intends to end the PHE on May 11, 2023. As Barry mentioned, we are providing our annual earnings guidance of $4.60 to $4.74 per diluted share, and annual revenue guidance of $3.55 billion to $3.62 billion. We have evaluated multiple scenarios, and based on the strength in our performance and the positive momentum we've seen in occupancy and strong skilled mix, as well as some additional strength in Medicaid and managed care programs, it gives us confidence that we will be able to achieve these results. are 2023 guidances based on diluted weighted average common shares outstanding of approximately $57.7 million, a tax rate of 25%, the inclusion of acquisitions anticipated to close in the first quarter of 2023, the inclusion of management expectations for FMAP grants, Medicare and Medicaid funding, and reimbursement rates net of provider tax, with the primary exclusion coming from stock-based compensation. Other additional factors that could impact quarterly performance include variations in reimbursement systems, delays and changes in state budgets, seasonality and occupancy and skilled mix, the influence of the general economy and census and staffing, the short-term impact of our acquisition activities, variations in insurance calls, surges in COVID-19 and other factors. And with that, I'll turn it over to Barry. Barry?
spk08: Thanks, Suzanne. We want to again thank everyone for joining us today and express our appreciation to our shareholders for their confidence and support. We know that this year will be not without some unique challenges. However, we're encouraged by our operational strength and our core business. As always, we want to recognize our talented field leaders for their heroic efforts, along with those of our nurses, therapists, and other frontline care providers who continue to provide an industry-leading example of life-enriching service to our residents, coworkers, and our communities. We're also appreciative to our colleagues at the service center who are working tirelessly to support our operations, enabling us to succeed in spite of the challenges we faced. Thank you for making us better every day. We'll now turn over to the Q&A portion of our call. Carmen, can you please instruct the audience on the Q&A procedure?
spk10: Thank you, and a reminder, To ask a question, simply press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press the star 11 again.
spk09: Please stand by while we compile the Q&A roster. And it comes from the line of Ben Hendrix with RBC Capital Markets.
spk10: Your line is open.
spk04: Hey guys, thank you very much. I just wanted to ask about your skilled mix momentum. Clearly we're seeing evidence of your higher acuity capabilities, but also some COVID and respiratory impacts in there as well. How should we think about steady state mix for your same store portfolio? And then from a modeling standpoint, how should we think about skilled mix evolving through the year? Thank you.
spk08: Yeah, I'll just, I'll speak generally about it and let Suzanne fill you in on any other insights she has. But, um, You know, as we compare kind of where we are today from a skilled mix standpoint to where we were both last quarter and last year, and even pre-COVID, we are pretty confident in the strength that we're building and the momentum that we're building in our ability to continue up the acuity chain and attract customers sicker patients, which is ultimately the goal. To be the best resource for our hospitals and managed care partners is always at the forefront of what we're thinking, and that means an evolution towards being nimble and adaptive to what their needs are, and their needs include ensuring that we have the capability to care for a more acute patient. So, you know, as we look at the impact of COVID this quarter, certainly it was a little bit higher than the same quarter last year. But comparable to kind of where we were last quarter, you know, what we see is that, you know, even though there was more COVID activity this quarter than there was in the same quarter last year, it's not much. And so... What that indicates to us is on a steady state basis, even in quarters where we're not really impacted by COVID, we're still fundamentally higher than where we were kind of going into this pandemic. And that momentum, it just continues. And so we're encouraged by that. Anything you want to add to that, Suzanne?
spk12: No, I think you said it really well. I think one of the things that we've been noticing for the last couple of quarters is a little bit less dependence on the waivers and maybe that, you know, COVID and our skills mix isn't as aligned. And so I think as Barry mentioned, I think we're really excited for where we are and the relationships that we've made throughout the entire year with our managed care partners continue to be strong. And as we continue to see that portion of the skills mix build,
spk04: Thank you. Just a quick follow-up. You've noted that states have been supportive of the PHE roll-off and the soft landing there, but is there any cadence, quarterly cadence considerations we need to be thinking about as we think about the second half of the year? Thanks.
spk12: Yeah, great question. Obviously, we have the announcement out there on the end of the PHE with the White House then leaning towards that May date. And so as we kind of look through that, you know, we're planning on getting some additional funding through that May date from the states that have been supportive. And as we've talked on previous calls, just a reminder, that was California, Arizona, and Texas. I think on the last call we talked about that California really has broken away from tying anything to the state of emergency. So they've really said that they're going to be supportive for the remainder of the year. So I feel great about California. Arizona has really thought through this good and well as they look to put the dollars in more into the rate. And so we've already started to see some of that come through in Arizona. And then Texas, I think, is the last one out there. They've kind of done a couple of things. They've looked at the the PHE, but they've also done some grants that we're expecting to see come in through the year. And then as we've talked to you guys about, there's that potential that we would have a hole between kind of when the state of emergency and the grants may not cover to the beginning of September. So I feel pretty good about how the states are lining up, what it's going to be a mix of kind of, you know, continued FMAP funding, additional rate funding, and then some of these grant programs that we've seen the states put in place. Barry, what did I miss?
spk08: I think that's it, Ben. I mean, ultimately, you know, I think as our guidance indicates, we feel pretty strong about, even though there are some small unknowns from state to state, overall, I think we feel like there's a pretty clear pathway for us to not have some massive blips on the state reimbursement front as FMAP fades. And like we mentioned earlier, it doesn't really just go away. It steps down. And so even with that step down, if there were no, like say it wasn't a bridge in Texas, for example, I don't think that would impact our outlook for the year at all.
spk05: That's great, guys. Thank you.
spk07: thank you one moment for our next question please and it comes from the line of koq with steve l please proceed hey good morning everyone uh congrats on closing the north american transaction um so barry you know i really appreciate the comment on the performance of the legend portfolio so on the uh north american assets I think Cyber has reported that their EBITDA rent coverage for these assets have been about 1.0 times. So it sounds like these should be created on day one. Are these California assets different from Legend or your typical turnaround opportunities if you look at them from either occupancy, skill mix, or cost saving potentials? And how long do you think it would take you to get your stabilization? And as a follow-up, could you also comment on the leadership pipeline and the current capacity to take on more assets?
spk08: Yeah, that's great questions, Tal. So, you know, this portfolio is an excellent one. It's one we've, you know, there was an opportunity to look at it a few years back. We were excited about it then. We know these buildings, they're buildings that we have competed with in the past. They're buildings that we have relationships with some of the leaders. And so we're really excited about this portfolio. We think it'll be a great addition. I will say this, not just about North America, but about transitions we're seeing in general. Given the labor challenges just globally, most buildings, and these are no exception, have high amounts of agency labor usage. And so, more than obviously typical, as we're seeing ourselves. But these in particular have quite a bit. And so, again, like with some of the recent ones we've taken on, the pathway for kind of a traditional recovery is somewhat hampered there. Getting agency out of a building in an environment like now is much more difficult, as you can imagine. So that's one of the primary challenges that we're facing is just to get to where we like to be as quick as we need to be is going to be challenged by the current state of labor. That said, these buildings are in really good condition clinically and have really good culture overall. I've been able to visit a few already. I've gotten to know some of the leaders of these buildings and some of the clinicians. And given the clinical stability that exists there, I think that provides us somewhat of an advantage for us to not say it's going to take forever. But it will take some time regardless. in spite of that. But again, like we mentioned in our prepared remarks, we take a long-term approach to these. We're not afraid of that challenge that exists. But we're going to go about it methodically and do it the right way. The other thing I'll mention, too, is just from an occupancy standpoint, the portfolio that we're taking on sits in the low 80s in terms of percentage. For California, that's pretty low. So that'll be another lever we're going to be focused on. And then just some other cost issues that we should be able to tackle more readily. But that all said, I don't think we're bullish enough to say these will be accretive this year, but one never knows. Hopefully the transition goes smoother than we hope it will, but we're planning on it being You know, in spite of all the challenges I've mentioned, we're anticipating these will be kind of on our normal cadence of being successful over the next few quarters.
spk16: Leadership.
spk08: From a leadership pipeline perspective, Tao, you know, we have a really strong stable of what we call administrators in training or CEOs in training. It's as strong as it's ever been, in spite of the fact that unemployment's pretty low. And that's a really good sign. We probably will be a little more tempered in our path of growth as we digest these 35 or so buildings we've taken in the last six months, as we have been in the past. But we actually, in spite of that, are geared to be able to take on... many more buildings, especially in other geographies where we haven't been as acquisitive lately. So we'll see. We'll be opportunistic, and we'll take a tempered approach to that. But we obviously will have more growth this year for sure. But it will probably come more in the latter half than in the next few months.
spk07: Yeah, thanks for the color there. My second question is, we noticed that the DSO ticked up a little bit sequentially. I think we also saw that in your 10K, you updated the risk disclosure around the growth of the Medicaid managed care organizations and the potential delay or reduction in Medicare reimbursement. Just curious if you have any general observations about the billing and collection trend for managed care in general. Anything worth calling out there?
spk12: Yeah, great question, and a couple of different aspects to that. Obviously, in the current quarter, for Q4, we had a lot of acquisitions. And so what we talk about, and just want to remind people, during stages of heavy acquisitions, our anticipated collections will be slower. That is just a normal part of doing acquisitions as we go through the change in ownership process and transfers everything over. As we kind of look for fourth quarter, it was just a little bit slower in the normal basis as well, and that really had to do with a lot of managed care organizations and a couple of states playing a little bit slower than that they normally do at the end of the year. With regards to the risk factor, what we added on, we did just want to highlight that there are more and more states that are changing from a direct pay system to a managed care system. Now almost all of our large states are all in managed Medicaid states. When the program goes from just a regular direct pay to managed Medicaid, the payments do come slower to us. And so one of our big states, California, switched in 2023 to that. And so we just want to give people a heads up that we'd expect some slowdown in our Medicaid collections in the state of California due to that transition.
spk07: Got you. And a final question, if I may, you know, if I look at the balance sheet, right, obviously that's under leveraged and you have abundant liquidity and very strong cash flow. You know, we're forecasting somewhere around $300 million operating cash flow and really $200 million free cash flow for the next two years. You know, just curious in terms of capital allocations, what are the things that you would prioritize? You know, I know that you have raised the dividend. You had a stock repurchase program last year. you know, how should we think about where you would allocate capital?
spk03: Yeah, Tal, I can take that as a chat. Certainly acquisitions would be the top of our list. You know, we see ourselves very much in growth mode and will continue to be. You know, and then obviously, you know, CapEx on the physical plants is another big spend, right? And, you know, one note on the cash flows too, you know, when we have larger, heavier periods of acquisition like we have over the last, you know, six months, that can tend to have a little bit of a drag on our cash flows as we see AR climb a little bit with just the nature of licensing and, you know, it's just part of kind of the process of a transition from one operator to another. So that will actually, you know, probably impact our cash flow a little bit. I think you'll see that. As we talked about a lot, we keep our balance sheet the way it is so that we can be ready when great opportunities arise. As I said in my prepared part of the script, I think we expect to see additional opportunities coming up this year and next. And we want to be prepared for that. So that's how we kind of look at the balance sheet.
spk12: And prepare both on the operating front as well as the standard bear rate front. So I think as we kind of look at that multifaceted ability to acquire, that would definitely be our number one use of those flows.
spk06: Great. Thank you for taking my questions.
spk10: Thank you. One moment for our next question, please. And it comes from the line of Scott Fidel with Stephens. Please go ahead.
spk13: Thanks. And hi, everyone. Actually, just wanted to pick that right up on that last topic just around operating cash flow. maybe get a little more visibility into what you're building into your outlook for next year. You've been running in that $275 million area for the last two years, and then you've talked about, you know, in the near term having some of these dynamics just around the acquisitions. Is it reasonable to think about operating cash flow stepping up a bit in 2023 just given the larger revenue scale, or are you assuming it, you know, remaining relatively stable with where it's been trending the last two years? then also what you're modeling for CapEx as well.
spk12: Yeah, great question, Scott. I think the one thing when you're looking at cash flows and you kind of think through the number of acquisitions that we've done, you know, our states can vary between four months and 18 months is the longest transition that we've ever had as they've got us on. And then so as you kind of think through where those cash flows go, we try to try to normalize it all and hope that they all come in, you know, kind of in the middle of that realm. And then after we get that licensing process done, then we have to go through the managed care process and get them recredentialed through their new license under managed care. So that's a secondary step. And again, that can take, you know, two to six months on top of that after you've already waited. And so It's a little bit of a waiting game, and so that's why we kind of, as you listen to Chad, of use of cash, one of the things that we'll probably end up having to do is use some of that working capital to get us through those child processes. Now our hope, and we have great systems and great processes, that it goes very succinctly, and we're on the early end of that. But unfortunately, we are at each individual state government's processing timeline a little bit here. with regards to how quickly it goes through. So I think it wouldn't be unreasonable to say, you know, we would expect kind of that same flow, net-net, because AR will grow.
spk03: Just a little bit there. California tends to be one of the slower states, too. Texas is faster than California, and so that's why it'll probably be a little more pronounced with this particular set of deals as well.
spk12: Right, and definitely different states have different things they turn off immediately. So Texas turns a lot more stuff off immediately, and so we get not a dollar in the door. In California, there's a little bit, we get some cash in the door quick, and then we have a turnoff period, and then it goes back on. So every state, again, we're talking super nuanced here, so a little bit up and down there.
spk08: We haven't talked a whole lot very recently about standard bearer, but we have been preparing for this and are still thinking a great deal about opportunities for standard bearer. Having cash availability for deals that, again, may not fit our operating footprint, but might be good real estate opportunities or something we always want to be ready for as well. Not signaling that we have anything in the works necessarily, but we have great hopes for Standard Bear to have some opportunities as well for growth.
spk13: Understood. And certainly you have tremendous amount of liquidity, but as we're just sort of honing in on trying to model the operating cash flow correctly, is it Maybe it's reasonable for us to think about that, those four Q dynamics persisting over the next quarter or two, and then you sort of get more of that cash flow normalization in the back half of the year. You think that's sort of a reasonable baseline assumption?
spk12: I think that's a reasonable baseline assumption. Yeah, a reasonable baseline assumption, knowing that we did, you know, just as much in Q1 as we did in Q4. And so I think it's a reasonable baseline. And then we can update you guys throughout the year, as we always do, as you see the cash come in or if we see someone extending with regards to the timing of the licensing process, which would make it last longer, or if they tighten up and they do a great job at the states, then you won't see it as pronounced in the cash flows.
spk13: Got it. And then just my second question, just interested if you could give us an update on your managed care contracting for 2023 and how you've seen your managed care rate trends sort of playing out relative to some of the inflationary dynamics. And Ben, just interested, too, if you've had a chance, I'm sure you've started this for sure, to just dig into the managed care contracting at the North American facilities and whether you see opportunities to improve the the managed care rates as you try to drive synergies off of those acquired properties.
spk12: Another great question. I think when you think through the dynamics that we have, we do have some of our larger contracts that we feel really good about, that they have recognition that labor has increased and overall cost has increased. And so we have At least one MCO provider who's actually recognized that. I think a lot of the other MCOs are looking and still struggling with regards to our overall cost increasing. And so they're kind of at their historical rates as a starting point, you know, anywhere between 2% and 3% as a starting point. But as we try to demonstrate to them the cost increases that we have had, I think that's the beginning of the negotiation. And so we've had some really good success with a few. There are some that are a little bit more holdout. So I think some of that progress and the negotiation time might go on a little bit longer because where we're asking for rates to increase is higher than they've historically done. And again, we've been very successful with some of the larger ones. And remember, we don't have For the most part, we don't have one contract that covers the entire company, but we really have a lot of smaller contracts so that what happens is we'll get wins throughout the year, and then that'll kind of come in over the entire period of the year.
spk14: Okay. All right, great. Okay, thanks.
spk10: Thank you. And with that, we end our Q&A session for today. I would like to turn the conference back to Mr. Barry Port for his closing remarks.
spk08: Thank you, everyone, for joining us today, and we look forward to a great year.
spk10: Thank you. And this concludes today's conference call. Thank you for participating, and you may now disconnect.
Disclaimer